There are 10 products in the pipeline for microbial keratitis, an ocular infection...
ONL Therapeutics trials ONL1204 to treat retinal detachment
Biopharmaceutical company ONL Therapeutics has commenced a Phase I clinical trial to assess its investigational drug, ONL1204, for the treatment of macula-off rhegmatogenous retinal detachment (RRD).
Focus shifts to gene therapy in the pipeline for treatment-resistant microbial keratitis
There are 10 products in the pipeline for microbial keratitis, an ocular infection of the cornea.
Two uveitis drugs show similarity in head-to-head study
An international, head-to-head clinical trial funded by the National Eye Institute has demonstrated similar performance by two uveitis drugs, methotrexate and mycophenolate mofetil.
Opthea reports positive data from Phase IIb trial in wet AMD
Australian biopharmaceutical firm Opthea has reported positive data from the Phase IIb clinical trial of OPT-302 in combination with ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration (AMD).
Oxurion reports mixed results from Phase IIa DME study
Oxurion has reported top-line results from the Phase IIa clinical trial of THR-317 in combination with ranibizumab to treat diabetic macular edema (DME) patients.
Outlook Therapeutics closes enrolment in Phase III wet AMD study
Outlook Therapeutics has concluded the enrolment of patients in a Phase III clinical trial of ONS-5010 for the treatment of patients with wet age-related macular degeneration (wet AMD).
ProQR to study new drug candidate for retinitis pigmentosa
ProQR Therapeutics has announced plans to conduct a Phase I/II clinical trial to evaluate QR-1123 for the treatment of patients with autosomal dominant retinitis pigmentosa (adRP).
Kodiak’s anti-VEGF antibody yields positive data in Phase Ib study
Kodiak Sciences has reported positive interim findings from an ongoing Phase Ib clinical trial of its anti-VEGF antibody biopolymer conjugate, KSI-301, for the treatment of three eye disorders.
Allergan and Editas to assess in-vivo CRISPR editing to treat LCA10
Allergan and Editas Medicine have launched a new Phase I/II clinical trial to assess CRISPR-based experimental medicine AGN-151587 (EDIT-101) for the treatment of Leber congenital amaurosis 10 (LCA10).
Immunocore, Pulse Infoframe to launch global patient registry for Uveal Melanoma
Immunocore and Pulse Infoframe are set to partner with academic institutions to launch first global patient registry for uveal melanoma (UM).